Product Name:	Anti-Mouse/Human CD44 [IM7] In Vivo Antibody - Low Endotoxin
Product Code:	IVMB0078
Size:	1mg, 5mg, 25mg, 50mg, 100mg
Clone:	IM7
Protein:	CD44
Product Type:	Monoclonal Antibody
Synonyms:	Hermes, Pgp-1, H-CAM, HUTCH-1, ECMR III, gp85, Ly-24
Isotype:	Rat IgG2b κ
Reactivity:	Human, Mouse
Immunogen:	Dexamethasone-induced myeloid leukemia M1 cells
Applications:	CyTOF®, ELISA Det, FC, ICC, IHC FF, IHC FFPE, IP, PhenoCycler®, WB
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Endotoxin Level:	< 1.0 EU/mg as determined by the LAL method
Purity:	≥95% monomer by analytical SEC >95% by SDS Page
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Product Code	Product Name	Endotoxin Level
IVMB0078	Anti-Mouse/Human CD44 [IM7] In Vivo Antibody - Low Endotoxin	Low
IVMB0079	Anti-Mouse/Human CD44 [IM7] In Vivo Antibody - Ultra Low Endotoxin	Ultra Low

Applications:	CODEX®, CyTOF®, ELISA Det, FC, ICC, IHC FF, IHC FFPE, IP, WB
Recommended Usage:	FC The suggested concentration for this IM7 antibody for staining cells in flow cytometry is ≤ 0.25 µg per 10⁶ in a volume of 100 µl or 100µl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this P84 antibody for use in western blotting is 1-10 µg/ml.
Reactivity:	Human, Mouse

Host Species:	Rat
Specificity:	Clone IM7 recognizes an epitope common to alloantigens and all isoforms of CD44 that is located between amino acids 145 and 186.
Antigen Distribution:	CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.
Immunogen:	Dexamethasone-induced myeloid leukemia M1 cells
Concentration:	≥ 5.0 mg/ml
Endotoxin Level:	< 1.0 EU/mg as determined by the LAL method
Purity:	≥95% monomer by analytical SEC >95% by SDS Page
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency.

Technical Datasheet:	View
Protein:	CD44
Function:	Leukocyte attachment and rolling on endothelial cells, stromal cells and ECM
Ligand/Receptor:	Hyaluronan, MIP-1β, fibronectin, collagen
Research Area:	Cell Adhesion, Cell Biology, Immunology, Stem Cell